glipizide has been researched along with exenatide in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Halperin, F; Ingelfinger, JR; McMahon, GT | 1 |
| Edgerton, LP; Elmore, LK; Patel, MB; Whalin, LM | 1 |
| Adanichkin, N; Campbell, JM; Kurmis, R; Munn, Z | 1 |
| Fralick, M; Gagne, JJ; Kesselheim, AS; Levin, R; Patorno, E | 1 |
| Abdul-Ghani, MA; Adams, AC; Adams, J; Cersosimo, E; Cheng, CC; DeFronzo, RA; Fourcaudot, M; Heikkinen, S; Khattab, A; Norton, L; Puckett, C; Samms, RJ; Triplitt, C; Tsintzas, K | 1 |
2 review(s) available for glipizide and exenatide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Pioglitazone; Rosiglitazone; Secretagogues; Sulfonylurea Compounds | 2018 |
1 trial(s) available for glipizide and exenatide
| Article | Year |
|---|---|
FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Fibroblast Growth Factors; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2022 |
3 other study(ies) available for glipizide and exenatide
| Article | Year |
|---|---|
Clinical decisions. Management of type 2 diabetes--polling results.
Topics: Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin, Isophane; Metformin; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2008 |
Combination exenatide-sitagliptin therapy used with glipizide in a patient with type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Female; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2012 |
Using Data From Routine Care to Estimate the Effectiveness and Potential Limitations of Outcomes-Based Contracts for Diabetes Medications.
Topics: Aged; Canagliflozin; Cohort Studies; Contracts; Diabetes Mellitus, Type 2; Exenatide; Female; Follow-Up Studies; Glipizide; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Middle Aged; Outcome Assessment, Health Care; Recombinant Fusion Proteins; Sitagliptin Phosphate | 2020 |